Hospitalizations

• 최근 연구에 따르면 업데이트된 백신 제형이 지난 시즌 동안 건강한 성인의 응급실 방문 및 입원율을 약 50% 감소시킨 것으로 나타났습니다. • 이러한 상당한 효능 개선은 백신 개발 및 공중 보건 보호 전략의 주요 진전을 의미합니다. • 이번 연구 결과는 2026년 4월 28일 CIDRAP의 최신 백신 정책 현황 보고서에 기록된 바와 같이, 진화하는 미국의 백신 정책 지형에 기여합니다.

• The U.S. daily COVID-19 case average increased by 13.3% over the past week, though hospitalizations continue to decline according to federal data. • About 48,000 patients are currently hospitalized with COVID-19, representing a decrease of nearly 104,000 patients over the past eight weeks, with hospital admissions down 11.7% weekly. • Alaska has the highest infection rate in the nation, followed by Montana, North Dakota, and Wyoming, while Puerto Rico, Florida, and Hawaii report the lowest rates.

• The SPIRIT-HF study, presented at ACC.26 in New Orleans (March 28-30, 2026), found that spironolactone increased hospitalizations and serious adverse events in patients with HFpEF (heart failure with preserved ejection fraction) or HFmrEF (mildly reduced ejection fraction). • Results raise significant safety questions about the drug's efficacy in these patient populations, potentially challenging current treatment protocols. • The findings were presented to cardiologists and cardiovascular specialists at the American College of Cardiology's annual conference, the largest gathering of heart disease specialists.

• Respiratory syncytial virus (RSV) hospitalizations declined 42% in the week ending March 20, 2026, compared to the peak surge in February, according to CDC surveillance data. • The decline follows the introduction of the first RSV vaccines approved for adults over 60 and high-risk populations, with over 8 million doses administered since January. • RSV typically causes severe disease in infants and older adults; the new vaccines represent a major breakthrough after decades of failed vaccine development efforts.